Literature DB >> 14594918

Cost-effectiveness of current and optimal treatment for schizophrenia.

Gavin Andrews1, Kristy Sanderson, Justine Corry, Cathy Issakidis, Helen Lapsley.   

Abstract

BACKGROUND: This paper is part of a project to identify the proportion of the burden of each mental disorder averted by current and optimal interventions, and the cost-effectiveness of both. AIMS: To use epidemiological data on schizophrenia to model the cost-effectiveness of current and optimal treatment.
METHOD: Calculate the burden of schizophrenia in the years lived with disability (YLD) component of disability-adjusted life-years lost, the proportion averted by current interventions, the proportion that could be averted by optimal treatment and the cost-effectiveness of both.
RESULTS: Current interventions avert some 13% of the burden, whereas 22% could be averted by optimal treatment. Current interventions cost about AUS 200,000 dollars per YLD averted, whereas optimal treatment at a similar cost could increase the number of YLDs averted by two-thirds. Even so, the majority of the burden of schizophrenia remains unavertable.
CONCLUSIONS: Optimal treatment is affordable within the present budget and should be implemented.

Entities:  

Mesh:

Year:  2003        PMID: 14594918     DOI: 10.1192/bjp.183.5.427

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  18 in total

1.  Using the effect size to model change in preference values from descriptive health status.

Authors:  Kristy Sanderson; Gavin Andrews; Justine Corry; Helen Lapsley
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

Review 2.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

3.  Experience base and system context in mental health care reform.

Authors:  Thomas Becker; Reinhold Kilian
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

4.  Receiving treatment, labor force activity, and work performance among people with psychiatric disorders: results from a population survey.

Authors:  Geoffrey Waghorn; David Chant
Journal:  J Occup Rehabil       Date:  2011-12

5.  Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis.

Authors:  Dan Chisholm; Oye Gureje; Sandra Saldivia; Marcelo Villalón Calderón; Rajitha Wickremasinghe; Nalaka Mendis; Jose-Luis Ayuso-Mateos; Shekhar Saxena
Journal:  Bull World Health Organ       Date:  2008-07       Impact factor: 9.408

6.  Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysis.

Authors:  Nicholas J K Breitborde; Scott W Woods; Vinod H Srihari
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

7.  Why schizophrenia epidemiology needs neurobiology--and vice versa.

Authors:  John J McGrath; Linda J Richards
Journal:  Schizophr Bull       Date:  2009-03-09       Impact factor: 9.306

8.  Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.

Authors:  Ramin Mojtabai; Laura Fochtmann; Su-Wei Chang; Roman Kotov; Thomas J Craig; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2009-06-08       Impact factor: 9.306

Review 9.  Canadian Practice Guidelines for Comprehensive Community Treatment for Schizophrenia and Schizophrenia Spectrum Disorders.

Authors:  Donald Addington; Elizabeth Anderson; Martina Kelly; Alain Lesage; Chris Summerville
Journal:  Can J Psychiatry       Date:  2017-09       Impact factor: 4.356

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.